Therapy of inflammatory bowel disease. (Q33951455)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Therapy of inflammatory bowel disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

7 November 2019

main subject

0 references

inflammation

0 references

author name string

B E Sands

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

issue

2 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

S68-82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

Inflammatory bowel disease (1)

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Epithelial cells as sensors for microbial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Expression and functional significance of an additional ligand for CTLA-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Signals and signs for lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Proteolytic enzymes in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Neuropeptides in inflammatory bowel disease: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Oxidants and free radicals in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Inhibition of delayed hypersensitivity by metronidazole and misonidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Double blind, placebo controlled trial of metronidazole in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Combination ciprofloxacin and metronidazole for active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Intensive intravenous treatment of ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Cortisone in ulcerative colitis; final report on a therapeutic trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Modulation by cytokines of glucocorticoid action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

7 January 2021

Nuclear factor-kappa B.

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Frequency of glucocorticoid resistance and dependency in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

New steroids for inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Molecular and cellular effects of methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Methotrexate for the Treatment of Crohn's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Immunosuppressive agents: recent developments in molecular action and clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Infliximab for the treatment of fistulas in patients with Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

The relationship between infliximab treatment and lymphoma in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Interleukin-10 gene knock-out mice: a model of chronic inflammation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Tacrolimus (FK-506) treatment of fulminant colitis in a child

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

IBD: A Vascular Disorder? The Case for Heparin Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Transdermal nicotine for active ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

A dose‐ranging pharmacokinetic study of nicotine tartrate following single‐dose delayed‐release oral and intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Nicotine tartrate liquid enemas for mildly to moderately active left‐sided ulcerative colitis unresponsive to first‐line therapy: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Therapeutic potential for blockade of the CD40 ligand, gp39.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Antibodies to interleukin 12 abrogate established experimental colitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease: toxins, mediators, and modulators of gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Novel therapies for inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0016-5085(00)70007-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0016-5085(00)70007-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10868899 AND SRC:MED&resulttype=core&format=json

7 November 2019

1 reference